We are live on
!
Find out more
VA
Verdad Advisers Portfolio holdings
AUM
$104M
This Fund
S&P 500
This Quarter
Est. Return
+21.07%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$104M
AUM Growth
+$15.6M
(+18%)
Cap. Flow
+$3.28M
Cap. Flow
% of AUM
3.14%
Top 10 Holdings %
Top 10 Hldgs %
18.12%
Holding
276
New
97
Increased
59
Reduced
42
Closed
66
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$2.13M |
| 2 |
Protara Therapeutics
TARA
|
+$1.49M |
| 3 |
X4 Pharmaceuticals
XFOR
|
+$1.44M |
| 4 |
Tyra Biosciences
TYRA
|
+$1.19M |
| 5 |
JBIO
Jade Biosciences
JBIO
|
+$1.18M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Micron Technology
MU
|
+$2.57M |
| 2 |
Revolution Medicines
RVMD
|
+$2.56M |
| 3 |
State Street
STT
|
+$2.11M |
| 4 |
Autohome
ATHM
|
+$2.11M |
| 5 |
Cal-Maine
CALM
|
+$1.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 50.7% |
| 2 | Technology | 15.71% |
| 3 | Financials | 9.07% |
| 4 | Communication Services | 7.06% |
| 5 | Consumer Discretionary | 5.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Vera Therapeutics
VERA
$2.52B
| $1.01M | 0.97% |
23,487
+13,306
| +131% | +$496K |
|
|
NUVL
27
DELISTED
Nuvalent
NUVL
| $1M | 0.96% |
+8,104
| New | +$872K |
|
28
Dianthus Therapeutics
DNTH
$6.03B
| $981K | 0.94% |
10,062
+1,363
| +16% | +$119K |
|
29
Aclaris Therapeutics
ACRS
$876M
| $927K | 0.89% |
175,272
-21,770
| -11% | -$97.1K |
|
30
Oppenheimer Holdings
OPY
$1.34B
| $915K | 0.88% |
8,673
+5,252
| +154% | +$535K |
|
31
Verizon
VZ
$210B
| $887K | 0.85% |
+20,938
| New | +$982K |
|
32
Myers Industries
MYE
$1.16B
| $865K | 0.83% |
+24,500
| New | +$577K |
|
33
Enliven Therapeutics
ELVN
$4.37B
| $861K | 0.82% |
+16,957
| New | +$720K |
|
34
Universal Insurance Holdings
UVE
$1.25B
| $850K | 0.81% |
+20,558
| New | +$775K |
|
|
BNY
35
Bank of New York Mellon
BNY
$111B
| $831K | 0.8% |
5,748
-3,203
| -36% | -$438K |
|
36
PC Connection
CNXN
$2.11B
| $809K | 0.77% |
+11,084
| New | +$739K |
|
|
AII
37
American Integrity Insurance
AII
$513M
| $794K | 0.76% |
42,178
+1,083
| +3% | +$19.6K |
|
38
Applied Materials
AMAT
$346B
| $787K | 0.75% |
1,089
-1,805
| -62% | -$833K |
|
39
AdaptHealth
AHCO
$856M
| $782K | 0.75% |
75,000
-20,000
| -21% | -$223K |
|
40
Allstate
ALL
$66.5B
| $780K | 0.75% |
+3,279
| New | +$713K |
|
41
Celldex Therapeutics
CLDX
$3.09B
| $770K | 0.74% |
+20,704
| New | +$669K |
|
|
42
Revolution Medicines
RVMD
$45.2B
| $759K | 0.73% |
4,053
-17,519
| -81% | -$2.56M |
|
43
Heritage Insurance Holdings
HRTG
$1.04B
| $745K | 0.71% |
28,575
+2,081
| +8% | +$51.9K |
|
44
TD Synnex
SNX
$21B
| $743K | 0.71% |
2,780
+1,334
| +92% | +$321K |
|
45
Movado Group
MOV
$750M
| $738K | 0.71% |
18,762
+8,019
| +75% | +$250K |
|
46
Smart Sand
SND
$227M
| $715K | 0.68% |
142,684
+19,988
| +16% | +$100K |
|
47
Viridian Therapeutics
VRDN
$2.6B
| $711K | 0.68% |
38,722
+7,543
| +24% | +$122K |
|
48
Design Therapeutics
DSGN
$941M
| $688K | 0.66% |
47,557
-44,753
| -48% | -$558K |
|
49
Marcus & Millichap
MMI
$1.22B
| $685K | 0.66% |
21,972
+6,433
| +41% | +$184K |
|
50
Mativ Holdings
MATV
$691M
| $681K | 0.65% |
+90,000
| New | +$775K |
|
Similar funds
IAP
JRSI
SFG
TPW
ACM
TOTUOP
XFP
ICVCFVA
Verdad Advisers's Q2 2026 Portfolio in Review
As of Q2 2026, Verdad Advisers held 276 positions worth $104M, up 18% from $88.8M the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Verdad Advisers deployed $3.28M of net new capital in Q2 2026, opening 97 new positions and adding to 59 existing holdings. Its largest new stake was Apple: 7,445 shares worth $2.15M.
By sector, the portfolio is most concentrated in Healthcare at 51% of assets, up from 42% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Micron Technology, an estimated $2.57M trimmed.
- Verdad Advisers's largest Q2 2026 buy was Apple: 7,445 shares worth $2.15M.
- Verdad Advisers added most to Comcast in Q2 2026, an estimated $1.11M increase.
- Verdad Advisers's biggest Q2 2026 reduction was Micron Technology, cutting an estimated $2.57M.
- Verdad Advisers fully exited State Street in Q2 2026, selling an estimated $2.11M.
- Verdad Advisers's ten largest holdings make up 18% of its $104M portfolio in Q2 2026.
- Verdad Advisers opened 97 new positions and closed 66 in Q2 2026.
- Verdad Advisers's portfolio value rose 18% quarter-over-quarter to $104M.
Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.